Country: United States
Language: English
Source: NLM (National Library of Medicine)
VALGANCICLOVIR HYDROCHLORIDE (UNII: 4P3T9QF9NZ) (GANCICLOVIR - UNII:P9G3CKZ4P5)
American Health Packaging
VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR 450 mg
ORAL
PRESCRIPTION DRUG
Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1)]. Prevention of CMV Disease: Valganciclovir tablets are indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) [see Clinical Studies (14.1)]. Prevention of CMV Disease : Valganciclovir tablets are indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see Clinical Studies (14.2)]. Valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component o
Valganciclovir Tablets USP, 450 mg are pink colored, oval shaped, film coated tablets debossed with ‘RDY’ on one side and ‘762’ on other side, and are supplied in: Unit dose package of 30 (5 x 6) NDC 68084-965-25. Store at 20°C-25°C (68°F-77°F) [See USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken.
Abbreviated New Drug Application
VALGANCICLOVIR- VALGANCICLOVIR TABLET, FILM COATED AMERICAN HEALTH PACKAGING ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE VALGANCICLOVIR TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR VALGANCICLOVIR TABLETS. VALGANCICLOVIR TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2001 WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_. HEMATOLOGIC TOXICITY: SEVERE LEUKOPENIA, NEUTROPENIA, ANEMIA, THROMBOCYTOPENIA, PANCYTOPENIA, AND BONE MARROW FAILURE INCLUDING APLASTIC ANEMIA HAVE BEEN REPORTED IN PATIENTS TREATED WITH VALGANCICLOVIR (5.1). IMPAIRMENT OF FERTILITY: BASED ON ANIMAL DATA, AND LIMITED HUMAN DATA, VALGANCICLOVIR MAY CAUSE TEMPORARY OR PERMANENT INHIBITION OF SPERMATOGENESIS IN MALES AND SUPPRESSION OF FERTILITY IN FEMALES. (5.3) FETAL TOXICITY: BASED ON ANIMAL DATA, VALGANCICLOVIR HAS THE POTENTIAL TO CAUSE BIRTH DEFECTS IN HUMANS. (5.4) MUTAGENESIS AND CARCINOGENESIS: BASED ON ANIMAL DATA, VALGANCICLOVIR HAS THE POTENTIAL TO CAUSE CANCERS IN HUMANS. (5.5) INDICATIONS AND USAGE Valganciclovir tablet is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients(1.1) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients(1.2) Prevention of CMV disease in kidney and heart transplant patients at high risk. DOSAGE AND ADMINISTRATION ADULT DOSAGE (2.2) Treatment of CMV retinitis Induction: 900 mg (two 450 mg tablets) twice a day for 21 days Maintenance: 900 mg (two 450 mg tablets) once a day Prevention of CMV disease in heart or kidney- pancreas transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation Prevention of CMV disease in kidney transplant patient Read the complete document